Compare Eli Lilly And Co (LLY) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Eli Lilly And Co trades at $1,231.9 (market cap $1.08T), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Eli Lilly And Co is far larger — about 1105× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Eli Lilly And Co pays a 0.57% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 94 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LLY | MRVI | |
|---|---|---|
Market Cap | $1.08T | $977.37M |
Volume | 2,520,401 | 2,742,564 |
Sector | Health | Health |
52-Week High | $1.28K | $9.00 |
52-Week Low | $799.57 | $2.83 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $1.12T | $1.08B |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,166.51, down 1.36% on the day, amid strong fundamentals with revenue surging to $65.18B in 2025 and net income reaching $20.64B. The stock exhibits a bullish technical trend, supported by moving averages, with key resistance near $1,190. Recent news highlights promising pipeline developments in weight-loss drugs, reinforcing growth prospects.
Outlook remains positive given robust earnings beats, high analyst buy ratings (73%), and a consensus price target of $1,350. Risks include competitive pressures and execution challenges in scaling production. The stock's premium valuation (P/E 39.16) warrants monitoring, but strong cash flow and innovation pipeline support long-term upside.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
